Healthcare
Replimune Group, Inc.(REPL)
Live Price
Offline$10.19
+1.90% today
1Y Change
-3.24%
Window
Jun 20, 2025 โ Jun 8, 2026
- Market Cap
- $210.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +5.2%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 20, 2025 โ Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Replimune Group, Inc. (REPL) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $10.19 and down 3.2% across the available one-year price window (Jun 20, 2025 โ Jun 8, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +5.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +5.2%, free cash flow -4.1% with operating margin 0.0% and ROIC -113.2%. Stock Foundry combines REPL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 28, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +5.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +40.7% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 28, 2026 | โ | +85.7% | +110.9% | โ |
2026 Feb 3, 2026 | -0.2% | -5.1% | +5.7% | -1.8% |
2025 Nov 6, 2025 | -3.5% | -2.2% | +5.6% | +24.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REPL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
REPL Max Drawdown
-86.54%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for REPL and SPY.
Company Overview
Replimune Group, Inc.
NASDAQ Global Select
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
- Leadership
- Sushil Patel
- IPO Date
- Jul 20, 2018
- Employees
- 479
- Street Address
- 500 Unicorn Park Drive
- Mailing
- Woburn, MA, 01801
- Region
- Woburn, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 222 9600
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.1
Growth
- Revenue
- 0.0%
- EPS
- +5.2%
- Free Cash Flow
- -4.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -102.7%
- ROIC
- -113.2%
Balance Sheet
- Debt/Equity
- 0.37
- Current Ratio
- 5.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.